BIOMAT Database Logo BIOMAT Database Logo

Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases. 1995

S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Department of Haematology, Hadassah Medical Center, Jerusalem, Israel.

BACKGROUND Therapy-related acute myeloid leukemia (t-AML) is a recognized entity complicating successful therapy for Hodgkin's disease (HD) and other neoplasias after many years. This risk appears to be related to cumulative exposure to alkylating agents and procarbazine, while drugs affecting DNA--topoisomerase II, such as epipodophyllotoxins and anthracyclines, are also associated with t-AML developing after a much shorter latent period. METHODS Of 56 patients with t-AML or myelodysplasia seen in our institutes during the period 1980-1994 we encountered 5 patients with acute promyelocytic leukemia (APL) all of whom had t(15;17). Four of these had been treated for HD with both chemotherapy and radiotherapy, and one with radiotherapy alone. RESULTS To the best of our knowledge these appear to be the first cases of t-AML in HD with cytogenetically proven t(15;17). Similarly to other cases of t-APL reported after therapy for neoplasias other than HD, these patients also have a relatively favorable prognosis as seen in de-novo APL. CONCLUSIONS Although rare, t-APL should be added to the list of late complications of therapy for HD.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014178 Translocation, Genetic A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome. Chromosomal Translocation,Translocation, Chromosomal,Chromosomal Translocations,Genetic Translocation,Genetic Translocations,Translocations, Chromosomal,Translocations, Genetic

Related Publications

S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Acute promyelocytic leukaemia and the t(15;17) translocation.
December 1993, Seminars in cancer biology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Hodgkin's disease and acute promyelocytic leukaemia. A case report.
September 1980, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Tetraploidy with double t(15;17)(q22;q21) in acute promyelocytic leukaemia.
February 2013, Pathology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
15/17 translocation in acute promyelocytic leukaemia following treatment of Hodgkin's disease.
January 1983, Clinical and laboratory haematology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
A (15;17) translocation not associated with acute promyelocytic leukaemia.
December 1996, British journal of haematology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Assessment of minimal residual disease in acute promyelocytic leukaemia with t(15;17) by chromosome painting.
July 1995, European journal of haematology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t(15;17): a report of two cases and a review of the literature.
September 2000, British journal of haematology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Molecular analysis of the t(15;17) translocation in acute promyelocytic leukaemia.
October 1992, Bailliere's clinical haematology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
A unique case of t(15;17) acute promyelocytic leukaemia (M3) developing into acute myeloblastic leukaemia (M1) with t(7;21) at relapse.
April 1993, British journal of haematology,
S Gillis, and O Sofer, and O Zelig, and E J Dann, and H Lotan, and D Ben Yehuda, and R Isacson, and E A Rachmilewitz, and I Ben-Bassat, and A Polliack
Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia.
January 1985, Nature,
Copied contents to your clipboard!